{"success":true,"data":{"pressRelease":{"id":"136961","rtpr_id":"nBw3510N3a-20260907","ticker":"ALIKO","exchange":"Euronext Paris","all_tickers":["ALIKO"],"title":"Aliko Scientific Successfully Launches U.S. Business Development Collaboration With Partner International at ADLM 2026, the World’s Largest Molecular Diagnostics Exhibition","author":"Business Wire","published_at":"2026-09-07T15:50:00.183Z","article_body":"Aliko Scientific Successfully Launches U.S. Business Development Collaboration\nWith Partner International at ADLM 2026, the World’s Largest Molecular\nDiagnostics Exhibition\n\n\n * Strong first joint initiative at ADLM (Association for Diagnostics &\nLaboratory Medicine) 2026, providing direct access to major international\ndiagnostics players\n\n * Significant interest generated in Aliko Scientific’s technologies, with\ndiscussions expected to progress into further business development activities\n\n * Strategic partnership opportunities identified to support the scale-up, U.S.\nmarket development and broader international expansion of Aliko Scientific\n\nRegulatory News:\n\nALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an\ninternational life sciences Group dedicated to integrated oncology\ndiagnostics, announces the successful launch of its collaboration with Partner\nInternational Inc., aimed at accelerating the Group’s development, notably\nin the United States, on the occasion of the ADLM 2026 exhibition in Anaheim,\nCalifornia.\n\nFrancesco Trisolini, CEO of Aliko Scientific, said: “We are extremely\nsatisfied with the way this collaboration has started. Within a very short\nperiod following the signing of the agreement, Partner International was able\nto organize a high-quality and very intensive agenda at ADLM, giving us direct\naccess to some of the most relevant players in the industry. The level of\ninterest we encountered confirms both the potential of our technologies and\nthe strategic importance of the U.S. market for Aliko Scientific.”\n\nJoanne Ball, CEO of Partner International, added: “Aliko Scientific has\nassembled a highly differentiated portfolio spanning cytology, automated FISH\nanalysis, advanced imaging and AI-enabled diagnostics. We believe there are\nsignificant opportunities to expand the adoption of these technologies\ninternationally, both through distribution and through broader strategic\nrelationships with established diagnostics and laboratory companies. We look\nforward to supporting Aliko Scientific in identifying and advancing these\nopportunities globally.”\n\nUnder the agreement, Partner International supports Aliko Scientific in the\ndevelopment of the U.S. market, with a particular focus on identifying and\napproaching new customers, distributors, commercial partners and potential\nstrategic opportunities in the life sciences and diagnostics sector. ADLM is\none of the world’s leading events for laboratory medicine and diagnostics\nand brought together more than 700 exhibitors across a broad range of\ndiagnostic and laboratory technologies.\n\nMore broadly, Partner International will work alongside Aliko Scientific to\nexpand the Group’s global commercial footprint, with activities focused on:\n\n\n * Identifying and securing qualified distributors across priority international\nmarkets;\n\n * Developing strategic partnerships with leading diagnostics, pathology and\nlaboratory companies;\n\n * Exploring technology integration and complementary product opportunities;\n\n * Expanding relationships with laboratory networks, healthcare organizations and\nother commercial partners; and\n\n * Supporting the progression of opportunities from initial engagement through\nnegotiation and agreement.\n\nThe first joint initiative proved highly successful confirming strong interest\nin Aliko Scientific’s technologies and commercial proposition, with several\ndiscussions expected to progress into further business development activities\nin the coming months.\n\nImportantly, these engaging talks with high-ranking interlocutors within large\norganizations of the diagnostics and life sciences industry highlighted the\npotential for strategic partnerships that could significantly support the\nscale-up and market penetration of Aliko Scientific’s technologies.\n\nThe United States represents the world’s largest healthcare and diagnostics\nmarket in terms of scale, volumes and commercial potential and remains a\npriority in Aliko Scientific’s international development strategy.\n\nThe initiative is part of Aliko Scientific’s broader strategy to strengthen\nits international commercial footprint, with a particular focus on\nhigh-potential markets for cytology, FISH, automated imaging and precision\noncology diagnostics.\n\nIn addition, Aliko Scientific continues to execute a strategy focused on\ncreating a global center of excellence in oncology diagnostics. Through\nIkonisys, the Group provides automated molecular cancer diagnostics combining\nhigh-precision microscopy, FISH analysis and artificial intelligence, while\nHospitex International brings expertise in precision cytology and standardized\nsample preparation.\n\nThe combination provides Aliko Scientific with an increasingly integrated\nportfolio capable of supporting laboratories across multiple stages of the\ndiagnostic workflow.\n\nFollowing the strong commercial interest generated at ADLM 2026, the\nengagement of Partner International represents another step in Aliko\nScientific’s strategy to accelerate international market penetration,\nestablish new distribution channels and develop strategic relationships\ncapable of expanding the global reach of the Group’s technologies.\n\n-----------------------\n\nAbout ALIKO SCIENTIFIC (Ikonisys SA)\n\nHeadquartered in Paris, ALIKO SCIENTIFIC is the parent company of an\ninternational ecosystem of businesses dedicated to advancing oncology\ndiagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the\ncompany coordinates industrial, financial and research activities through its\nsubsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO\nSCIENTIFIC’s mission is to innovate cancer diagnosis by uniting cutting-edge\ntechnologies, resources, and strategic investments to create a global center\nof excellence in oncology.\n\nFor more information, visit: www.alikoscientific.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.alikoscientific.com&esheet=54599779&newsitemid=20260907375555&lan=en-US&anchor=www.alikoscientific.com&index=1&md5=f67458b29e97cd5723475ea9602203e1)\n\nAbout IKONISYS\n\nIkonisys is a global leader in automated diagnostics, specializing in\nfluorescence in situ hybridization (FISH) and circulating tumor cell (CTC)\ndetection. Leveraging advanced artificial intelligence (AI) and a fully\nautomated microscopy platform, Ikonisys provides unmatched precision,\nscalability, and efficiency in cancer diagnostics and treatment monitoring.\nRecognized as pioneer in automation for rare cell detection, Ikonisys is at\nthe forefront of personalized medicine, empowering clinicians to deliver\ntargeted therapies and improve patient outcomes.\n\nFor more information, visit: www.ikonisys.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fikonisys.com%2F&esheet=54599779&newsitemid=20260907375555&lan=en-US&anchor=www.ikonisys.com&index=2&md5=2a0d1d94a529b4705fdb35805d68861b)\n\nAbout PARTNER INTERNATIONAL\n\nPartner International is a global life sciences business development\norganization supporting pharmaceutical, biotechnology, medical technology and\ndiagnostics companies in the identification and execution of strategic\ntransactions and commercial partnerships. With more than 25 years of\nexperience and a proprietary global network of more than 45,000 senior\nindustry executives and decision-makers, Partner International supports\nclients across partnering, licensing, distribution, strategic alliances,\nM&A and other business development initiatives. Partner International\noperates internationally across North America, Europe and Asia, providing\nclients with senior-level business development resources and structured,\ntargeted access to potential partners worldwide.\n\nFor more information, visit: partner-intl.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fpartner-intl.com%2F&esheet=54599779&newsitemid=20260907375555&lan=en-US&anchor=partner-intl.com&index=3&md5=261f446eb81692ada40d50d7e5b453e6)\n\nAbout HOSPITEX\n\nHospitex, based in Florence, Italy, is a global leader in cytology innovation.\nThe company conducts in-house research, development, and production, thus\nensuring the highest standards of quality. Hospitex offers the world’s most\nadvanced Liquid-Based Cytology (LBC) technology, capable of processing any\ncytological sample with unmatched precision. Hospitex is uniquely positioned\nas the only company fully prepared for seamless digital integration, paving\nthe way for a transformative future in cytology diagnostics.\n\nFor more information, visit: www.hospitex.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhospitex.com%2F&esheet=54599779&newsitemid=20260907375555&lan=en-US&anchor=www.hospitex.com&index=4&md5=abaf0a169e371d825f48c67f783f0b97)\n\nDisclaimer\n\nThis press release contains forward-looking statements about the Company’s\nprospects and development. These statements are sometimes identified by the\nuse of the future tense, the conditional tense and forward-looking words such\nas “believe”, “aim to”, “expect”, “intend”, “estimate”,\n“believe”, “should”, “could”, “would” or “will” or, where\nappropriate, the negative of these terms or any other similar variants or\nexpressions. This information is not historical data and should not be\nconstrued as a guarantee that the facts and data set forth will occur. This\ninformation is based on data, assumptions and estimates considered reasonable\nby the Company. It is subject to change or modification due to uncertainties\nrelating to the economic, financial, competitive and regulatory environment.\nThis information contains data relating to the Company’s intentions,\nestimates and objectives concerning, in particular, the market, strategy,\ngrowth, results, financial situation and cash flow of the Company. The\nforward-looking information contained in this press release is made only as of\nthe date of this press release. The Company does not undertake to update any\nforward-looking information contained in this press release, except as\nrequired by applicable law or regulation. The Company operates in a\ncompetitive and rapidly changing environment and therefore cannot anticipate\nall of the risks, uncertainties or other factors that may affect its business,\ntheir potential impact on its business or the extent to which the\nmaterialization of any one risk or combination of risks could cause results to\ndiffer materially from those expressed in any forward-looking information, it\nbeing recalled that none of this forward-looking information constitutes a\nguarantee of actual results.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260907375555/en/\n(https://www.businesswire.com/news/home/20260907375555/en/)\n\nIkonisys \n\nAlessandro Mauri\n\nCFO\n\ninvestors@ikonisys.com (mailto:investors@ikonisys.com)\n\nNewCap \n\nLouis-Victor Delouvrier/Alexandre Massias\n\nInvestor Relations\n\nIkonisys@newcap.eu \n(mailto:ikonisys@newcap.eu) \nTel.: +33 (0)1 44 71 94 94\n\nNewCap \n\nNicolas Mérigeau\n\nMedia Relations\n\nIkonisys@newcap.eu \n(mailto:ikonisys@newcap.eu) \nTel.: +33 (0)1 44 71 94 98\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw3510N3a-20260907","title":"Aliko Scientific Successfully Launches U.S. Business Development Collaboration With Partner International at ADLM 2026, the World’s Largest Molecular Diagnostics Exhibition","author":"Business Wire","ticker":"ALIKO","created":"2026-09-07T15:50:00.183Z","tickers":["ALIKO"],"exchange":"Euronext Paris","article_body":"Aliko Scientific Successfully Launches U.S. Business Development Collaboration\nWith Partner International at ADLM 2026, the World’s Largest Molecular\nDiagnostics Exhibition\n\n\n * Strong first joint initiative at ADLM (Association for Diagnostics &\nLaboratory Medicine) 2026, providing direct access to major international\ndiagnostics players\n\n * Significant interest generated in Aliko Scientific’s technologies, with\ndiscussions expected to progress into further business development activities\n\n * Strategic partnership opportunities identified to support the scale-up, U.S.\nmarket development and broader international expansion of Aliko Scientific\n\nRegulatory News:\n\nALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an\ninternational life sciences Group dedicated to integrated oncology\ndiagnostics, announces the successful launch of its collaboration with Partner\nInternational Inc., aimed at accelerating the Group’s development, notably\nin the United States, on the occasion of the ADLM 2026 exhibition in Anaheim,\nCalifornia.\n\nFrancesco Trisolini, CEO of Aliko Scientific, said: “We are extremely\nsatisfied with the way this collaboration has started. Within a very short\nperiod following the signing of the agreement, Partner International was able\nto organize a high-quality and very intensive agenda at ADLM, giving us direct\naccess to some of the most relevant players in the industry. The level of\ninterest we encountered confirms both the potential of our technologies and\nthe strategic importance of the U.S. market for Aliko Scientific.”\n\nJoanne Ball, CEO of Partner International, added: “Aliko Scientific has\nassembled a highly differentiated portfolio spanning cytology, automated FISH\nanalysis, advanced imaging and AI-enabled diagnostics. We believe there are\nsignificant opportunities to expand the adoption of these technologies\ninternationally, both through distribution and through broader strategic\nrelationships with established diagnostics and laboratory companies. We look\nforward to supporting Aliko Scientific in identifying and advancing these\nopportunities globally.”\n\nUnder the agreement, Partner International supports Aliko Scientific in the\ndevelopment of the U.S. market, with a particular focus on identifying and\napproaching new customers, distributors, commercial partners and potential\nstrategic opportunities in the life sciences and diagnostics sector. ADLM is\none of the world’s leading events for laboratory medicine and diagnostics\nand brought together more than 700 exhibitors across a broad range of\ndiagnostic and laboratory technologies.\n\nMore broadly, Partner International will work alongside Aliko Scientific to\nexpand the Group’s global commercial footprint, with activities focused on:\n\n\n * Identifying and securing qualified distributors across priority international\nmarkets;\n\n * Developing strategic partnerships with leading diagnostics, pathology and\nlaboratory companies;\n\n * Exploring technology integration and complementary product opportunities;\n\n * Expanding relationships with laboratory networks, healthcare organizations and\nother commercial partners; and\n\n * Supporting the progression of opportunities from initial engagement through\nnegotiation and agreement.\n\nThe first joint initiative proved highly successful confirming strong interest\nin Aliko Scientific’s technologies and commercial proposition, with several\ndiscussions expected to progress into further business development activities\nin the coming months.\n\nImportantly, these engaging talks with high-ranking interlocutors within large\norganizations of the diagnostics and life sciences industry highlighted the\npotential for strategic partnerships that could significantly support the\nscale-up and market penetration of Aliko Scientific’s technologies.\n\nThe United States represents the world’s largest healthcare and diagnostics\nmarket in terms of scale, volumes and commercial potential and remains a\npriority in Aliko Scientific’s international development strategy.\n\nThe initiative is part of Aliko Scientific’s broader strategy to strengthen\nits international commercial footprint, with a particular focus on\nhigh-potential markets for cytology, FISH, automated imaging and precision\noncology diagnostics.\n\nIn addition, Aliko Scientific continues to execute a strategy focused on\ncreating a global center of excellence in oncology diagnostics. Through\nIkonisys, the Group provides automated molecular cancer diagnostics combining\nhigh-precision microscopy, FISH analysis and artificial intelligence, while\nHospitex International brings expertise in precision cytology and standardized\nsample preparation.\n\nThe combination provides Aliko Scientific with an increasingly integrated\nportfolio capable of supporting laboratories across multiple stages of the\ndiagnostic workflow.\n\nFollowing the strong commercial interest generated at ADLM 2026, the\nengagement of Partner International represents another step in Aliko\nScientific’s strategy to accelerate international market penetration,\nestablish new distribution channels and develop strategic relationships\ncapable of expanding the global reach of the Group’s technologies.\n\n-----------------------\n\nAbout ALIKO SCIENTIFIC (Ikonisys SA)\n\nHeadquartered in Paris, ALIKO SCIENTIFIC is the parent company of an\ninternational ecosystem of businesses dedicated to advancing oncology\ndiagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the\ncompany coordinates industrial, financial and research activities through its\nsubsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO\nSCIENTIFIC’s mission is to innovate cancer diagnosis by uniting cutting-edge\ntechnologies, resources, and strategic investments to create a global center\nof excellence in oncology.\n\nFor more information, visit: www.alikoscientific.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.alikoscientific.com&esheet=54599779&newsitemid=20260907375555&lan=en-US&anchor=www.alikoscientific.com&index=1&md5=f67458b29e97cd5723475ea9602203e1)\n\nAbout IKONISYS\n\nIkonisys is a global leader in automated diagnostics, specializing in\nfluorescence in situ hybridization (FISH) and circulating tumor cell (CTC)\ndetection. Leveraging advanced artificial intelligence (AI) and a fully\nautomated microscopy platform, Ikonisys provides unmatched precision,\nscalability, and efficiency in cancer diagnostics and treatment monitoring.\nRecognized as pioneer in automation for rare cell detection, Ikonisys is at\nthe forefront of personalized medicine, empowering clinicians to deliver\ntargeted therapies and improve patient outcomes.\n\nFor more information, visit: www.ikonisys.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fikonisys.com%2F&esheet=54599779&newsitemid=20260907375555&lan=en-US&anchor=www.ikonisys.com&index=2&md5=2a0d1d94a529b4705fdb35805d68861b)\n\nAbout PARTNER INTERNATIONAL\n\nPartner International is a global life sciences business development\norganization supporting pharmaceutical, biotechnology, medical technology and\ndiagnostics companies in the identification and execution of strategic\ntransactions and commercial partnerships. With more than 25 years of\nexperience and a proprietary global network of more than 45,000 senior\nindustry executives and decision-makers, Partner International supports\nclients across partnering, licensing, distribution, strategic alliances,\nM&A and other business development initiatives. Partner International\noperates internationally across North America, Europe and Asia, providing\nclients with senior-level business development resources and structured,\ntargeted access to potential partners worldwide.\n\nFor more information, visit: partner-intl.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fpartner-intl.com%2F&esheet=54599779&newsitemid=20260907375555&lan=en-US&anchor=partner-intl.com&index=3&md5=261f446eb81692ada40d50d7e5b453e6)\n\nAbout HOSPITEX\n\nHospitex, based in Florence, Italy, is a global leader in cytology innovation.\nThe company conducts in-house research, development, and production, thus\nensuring the highest standards of quality. Hospitex offers the world’s most\nadvanced Liquid-Based Cytology (LBC) technology, capable of processing any\ncytological sample with unmatched precision. Hospitex is uniquely positioned\nas the only company fully prepared for seamless digital integration, paving\nthe way for a transformative future in cytology diagnostics.\n\nFor more information, visit: www.hospitex.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhospitex.com%2F&esheet=54599779&newsitemid=20260907375555&lan=en-US&anchor=www.hospitex.com&index=4&md5=abaf0a169e371d825f48c67f783f0b97)\n\nDisclaimer\n\nThis press release contains forward-looking statements about the Company’s\nprospects and development. These statements are sometimes identified by the\nuse of the future tense, the conditional tense and forward-looking words such\nas “believe”, “aim to”, “expect”, “intend”, “estimate”,\n“believe”, “should”, “could”, “would” or “will” or, where\nappropriate, the negative of these terms or any other similar variants or\nexpressions. This information is not historical data and should not be\nconstrued as a guarantee that the facts and data set forth will occur. This\ninformation is based on data, assumptions and estimates considered reasonable\nby the Company. It is subject to change or modification due to uncertainties\nrelating to the economic, financial, competitive and regulatory environment.\nThis information contains data relating to the Company’s intentions,\nestimates and objectives concerning, in particular, the market, strategy,\ngrowth, results, financial situation and cash flow of the Company. The\nforward-looking information contained in this press release is made only as of\nthe date of this press release. The Company does not undertake to update any\nforward-looking information contained in this press release, except as\nrequired by applicable law or regulation. The Company operates in a\ncompetitive and rapidly changing environment and therefore cannot anticipate\nall of the risks, uncertainties or other factors that may affect its business,\ntheir potential impact on its business or the extent to which the\nmaterialization of any one risk or combination of risks could cause results to\ndiffer materially from those expressed in any forward-looking information, it\nbeing recalled that none of this forward-looking information constitutes a\nguarantee of actual results.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260907375555/en/\n(https://www.businesswire.com/news/home/20260907375555/en/)\n\nIkonisys \n\nAlessandro Mauri\n\nCFO\n\ninvestors@ikonisys.com (mailto:investors@ikonisys.com)\n\nNewCap \n\nLouis-Victor Delouvrier/Alexandre Massias\n\nInvestor Relations\n\nIkonisys@newcap.eu \n(mailto:ikonisys@newcap.eu) \nTel.: +33 (0)1 44 71 94 94\n\nNewCap \n\nNicolas Mérigeau\n\nMedia Relations\n\nIkonisys@newcap.eu \n(mailto:ikonisys@newcap.eu) \nTel.: +33 (0)1 44 71 94 98\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-07T15:50:00.218209239Z","server_sent_at_ms":1788796200218},"received_at":"2026-09-07T15:50:00.277Z","source_url":"https://www.businesswire.com/news/home/20260907375555/en/"},"analysis":{"id":"125839","press_release_id":"136961","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":["no signed commercial agreements, revenue, or deal terms disclosed -- only exploratory discussions","promotional tone typical of IR-driven Euronext Growth release with no quantitative backing"],"eventType":"partnership","narrative":"Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) launched its U.S. business development collaboration with Partner International at ADLM 2026 in Anaheim, an exhibition that drew more than 700 diagnostics exhibitors.\n\nCEO Francesco Trisolini reported direct access to major industry players and strong interest in the company's technologies, with several discussions expected to progress into further business development activities in the coming months.\n\nPartner International will identify U.S. and international customers, distributors and strategic partners as Aliko targets the United States, which it calls the world's largest healthcare and diagnostics market.\n\nNo signed commercial agreements or financial terms were disclosed; the effort supports an integrated oncology diagnostics portfolio combining Ikonisys' automated FISH and AI microscopy with Hospitex International's precision cytology.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap oncology diagnostics player ramps U.S. market entry via Partner International -- the test will be converting ADLM interest into signed distribution deals."},"keyFigures":{"customDimensions":{"adlm_2026_exhibitors":"more than 700","partner_international_network_executives":"more than 45,000"}},"quotedText":"We are extremely\nsatisfied with the way this collaboration has started.","namedEntities":{"people":[{"name":"Francesco Trisolini","role":"CEO of Aliko Scientific"},{"name":"Joanne Ball","role":"CEO of Partner International"},{"name":"Alessandro Mauri","role":"CFO of Ikonisys"}],"products":["automated FISH analysis","AI-enabled diagnostics","automated molecular cancer diagnostics","Liquid-Based Cytology (LBC) technology","circulating tumor cell (CTC) detection"],"companies":[{"name":"Aliko Scientific (Ikonisys SA)","ticker":"ALIKO","relationship":"filer"},{"name":"Partner International Inc.","relationship":"business development partner"},{"name":"Ikonisys Inc. (USA)","relationship":"subsidiary"},{"name":"Hospitex International (Italy)","relationship":"subsidiary"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"The collaboration with Partner International launched and generated strong interest at ADLM 2026, but there are no signed commercial agreements, revenues, or deal terms -- only exploratory discussions expected to progress. Early-stage business development news for a micro-cap foreign-listed issuer."},"tickerRelevance":{"others":[],"primary":"ALIKO"},"globalImportance":12,"audienceRelevance":8,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap foreign listed (Euronext Growth Paris)","eventGravity":"early-stage business development collaboration launch","issuerAuthored":true,"householdBrandBoost":false,"quantitativeBacking":"none -- no financial metrics or signed deals disclosed","retailFavoriteBoost":false}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) launched its U.S. business development collaboration with Partner International at ADLM 2026 in Anaheim, an exhibition that drew more than 700 diagnostics exhibitors.\n\nCEO Francesco Trisolini reported direct access to major industry players and strong interest in the company's technologies, with several discussions expected to progress into further business development activities in the coming months.\n\nPartner International will identify U.S. and international customers, distributors and strategic partners as Aliko targets the United States, which it calls the world's largest healthcare and diagnostics market.\n\nNo signed commercial agreements or financial terms were disclosed; the effort supports an integrated oncology diagnostics portfolio combining Ikonisys' automated FISH and AI microscopy with Hospitex International's precision cytology.","key_figures":{"customDimensions":{"adlm_2026_exhibitors":"more than 700","partner_international_network_executives":"more than 45,000"}},"named_entities":{"people":[{"name":"Francesco Trisolini","role":"CEO of Aliko Scientific"},{"name":"Joanne Ball","role":"CEO of Partner International"},{"name":"Alessandro Mauri","role":"CFO of Ikonisys"}],"products":["automated FISH analysis","AI-enabled diagnostics","automated molecular cancer diagnostics","Liquid-Based Cytology (LBC) technology","circulating tumor cell (CTC) detection"],"companies":[{"name":"Aliko Scientific (Ikonisys SA)","ticker":"ALIKO","relationship":"filer"},{"name":"Partner International Inc.","relationship":"business development partner"},{"name":"Ikonisys Inc. (USA)","relationship":"subsidiary"},{"name":"Hospitex International (Italy)","relationship":"subsidiary"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-07T15:52:09.546Z","global_importance":12,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap foreign listed (Euronext Growth Paris)","eventGravity":"early-stage business development collaboration launch","issuerAuthored":true,"householdBrandBoost":false,"quantitativeBacking":"none -- no financial metrics or signed deals disclosed","retailFavoriteBoost":false}},"durationMs":null,"modelName":"glm-4.7"}}